Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 124-135

  Luo, Nanlan ^a   Chung, B Hong ^a   Wang, Xiangdong ^b   Klein, Richard L ^c   Tang, Chao Ke ^d   Garvey, W Timothy ^a,e   Fu, Yuchang ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SHANDONG UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF SOUTH CHINA   (China)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Adiponectin receptor; Macrophage foam cells; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; CHOLESTEROL; GLUCOSE; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR A 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTERY WALL; ARTICLE; BODY FAT; BODY WEIGHT; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RESPONSE; ENHANCER REGION; FATTY LIVER; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; CARRIER PROTEINS; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; FATTY LIVER; FOAM CELLS; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; INSULIN; LIVER; MACROPHAGES, PERITONEAL; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SKELETAL; PROMOTER REGIONS, GENETIC; RECEPTORS, ADIPONECTIN; TRIGLYCERIDES;

EID: 84876804378     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.02.026     Document Type: Article

References (51)

1. DeFronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
2. Reaven G.M. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1606.
3. Reaven G.M. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Diabetes Care 1991, 14:195-202.
4. Nigro J., Osman N., Dart A.M., Little P.J. Insulin resistance and atherosclerosis. Endocr Rev 2006, 27:242-259.
5. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002, 13:84-89.
6. Pajvani U.B., Hawkins M., Combs T.P., et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279:12152-12162.
7. Lara-Castro C., Fu Y., Chung B.H., Garvey W.T. Adiponectin and the metabolic syndrome: mechanisms mediating the risk of metabolic and cardiovascular disease. Curr Opin Lipidol 2007, 18:263-270.
8. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
9. Lindsay R.S., Funahashi T., Hanson R.L., et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360:57-58.
10. Lindsay R.S., Funahashi T., Krakoff J., et al. Genome-wide linkage analysis of serum adiponectin in the Pima Indian population. Diabetes 2003, 52:2419-2425.
11. Fruebis J., Tsao T.S., Javorschi S., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005-2010.
12. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
13. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
14. Combs T.P., Berg A.H., Obici S., Scherer P.E., Rossetti L. Endogenous glucose production is inhibited by the adiposederived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
15. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
16. Furukawa K., Hori M., Ouchi N., et al. Adiponectin down-regulates acyl-coenzyme A: cholesterol acyltransferase-1 in cultured human monocyte-derived macrophages. Biochem Biophys Res Commun 2004, 317:831-836.
17. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and apoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
18. Combs T.P., Pajvani U.B., Berg A.H., et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 2004, 145:367-383.
19. Fu Y., Luo N., Klein R.L., Garvey W.T. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005, 46:1369-1379.
20. Waki H., Yamauchi T., Kamon J., et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem 2003, 278:40352-40363.
21. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423:762-769.
22. Mao X., Kikani C.K., Riojas R.A., et al. APPL1 bonds to adiponectin receptors and mediates adiponectin signaling and function. Nat Cell Biol 2006, 8:516-523.
23. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A 2004, 101:10308-10313.
24. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobeet K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
25. Yamauchi T., Nio Y., Maki T., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
26. Chinetti G., Zawadski C., Fruchart J.C., Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR. Biochem Biophys Res Commun 2004, 314:151-158.
27. Yamaguchi N., Argueta J.G., Masuhiro Y., et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005, 579:6821-6826.
28. Tian L., Luo N., Zhu X., Chung B.H., Garvey W.T., Fu Y. Adiponectin-AdipoR1/2-APPL1 signaling axis suppresses human foam cell formation: differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis 2012, 221:66-75.
29. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
30. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
31. Bouloumie A., Curat C.A., Sengenes C., Lolmede K., Miranville A., Busse R. Role of macrophage tissue infiltration in metabolic diseases. Curr Opin Clin Nutr Metab Care 2005, 8:347-354.
32. Kanda H., Tateya S., Tamori Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116:1494-1505.
33. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
34. Xu H., Barnes G.T., Yang Q., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
35. Li P., Lu M., Nguyen M.T., et al. Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J Biol Chem 2010, 285:15333-15345.
36. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
37. Oh D.Y., Talukdar S., Bae E.J., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
38. Saberi M., Woods N.B., de Luca C., et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 2009, 10:419-429.
39. Luo N., Liu J., Chung B.H., et al. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 2010, 59:791-799.
40. Luo N., Wang X., Chung B.H., et al. Effects of macrophage-specific adiponectin expression on lipid metabolism in vivo. Am J Physiol Endocrinol Metab 2011, 301:E180-E186.
41. Maeda K., Cao H., Kono K., et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005, 1:107-119.
42. Wredenberg A., Freyer C., Sandström M.E., et al. Respiratory chain dysfunction in skeletal muscle does not cause insulin resistance. Biochem Biophys Res Commun 2006, 350:202-207.
43. Garvey W.T., Maianu L., Zhu J.H., Brechtel-Hook G., Wallace P., Baron A.D. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 1998, 101:2377-2386.
44. Yoon J.C., Puigserver P., Chen G., et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001, 413:131-138.
45. Ramirez-Zacarias J.L., Castro-Munozledo F., Kuri-Harcuch W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 1992, 97:493-497.
46. Kunita E., Yamamoto H., Kitagawa T., et al. Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation. Circ J 2012, 76:1687-1696.
47. Ohashi T., Shibata R., Morimoto T., et al. Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. Atherosclerosis 2010, 212:237-242.
48. Broedl U.C., Lebherz C., Lehrke M., et al. Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques. PLoS One 2009, 4:e4733.
49. Rizza S., Gigli F., Galli A., et al. Adiponectin isoforms in elderly patients with or without coronary artery disease. J Am Geriatr Soc 2010, 58:702-706.
50. Yamauchi T., Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013, 17:185-196.
51. Tian L., Luo N., Klein R.L., Chung B.H., Garvey W.T., Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009, 202:152-161.